Background: Following systemic delivery, AAV9-mediated gene expression is
hemophilia. 6 Furthermore, AAV has shown promise in a number of clinical studies with respect to treating hemophilia, 7 mucopolysaccharidosis type IIIA 8 and inherited retinopathy. 9 To date, hundreds of AAV serotypes have been identified that infect human and primate species. 10 Among them, AAV8 and AAV9 have emerged as leading serotypes for targeting skeletal and cardiac muscle. AAV9 also shows potential for crossing the blood-brain barrier, which could afford therapeutic potential for neurologic disorders or could potentiate untoward side effects if the brain is not the desired target.
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In humans, peripheral arterial disease (PAD) is caused by atherosclerotic blockages that reduce blood flow to the leg(s) and, in pre-clinical models, PAD is typically approximated by femoral artery ligation and/or excision. Most pre-clinical AAV studies to date on PAD have used local intramuscular (IM) injection. In previous studies,
AAV vectors expressing EcSOD from the cytomegalovirus (CMV)
promoter were cross-packaged into AAV9 capsids and IM injected into hind-limb muscle just prior to femoral excision/ligation. 12 We found that AAV9-mediated overexpression of EcSOD in ischemic skeletal muscle significantly improved the recovery of perfusion ratio and capillary density, whereas apoptotic nuclei and limb necrosis were decreased. 12 In another study, a combination gene therapy using an AAV vector expressing both FGF2 and Cyr61 from the CMV promoter was tested after IM injection into ischemic hindlimb muscles, and a therapeutic benefit was observed superior to that obtained after IM injection of the corresponding bicistronic plasmid (pC-FGFiCyr). 13 In other studies, hindlimb ischemia was induced in BALB/c mice IM injected with a conditionally silenced AAV vector expressing human vascular endothelial growth factor. It was found that AAV-mediated gene therapy reversibly activated angiogenic and vasculogenic genes with no apparent adverse side effects. 14 Thus, although the IM injection of AAV has shown promise in mice, IM injection is predictably far less effective in humans and results in a far less homogeneous distribution of gene expression because of the > 1000-fold increase in muscle mass. 15 By contrast, the intravenous (IV) administration of AAV vectors has the benefit of offering a perfectly homogeneous distribution of gene expression. One potential concern in the setting of PAD is that systemic delivery to ischemic muscle might be limited in proportion to the reduction in blood flow. Somewhat unexpectedly, in a previous study, AAV9-mediated gene expression after IV administration was 30-150-fold higher in ischemic versus non-ischemic muscle. 16 In the present study, we aimed to clarify the mechanism(s) underlying the dramatic improvement in AAV9-mediated gene expression seen in ischemic muscle following systemic delivery. 
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Our previous work demonstrated that terminal N-linked galactosyl residues are predominantly sialylated on normal myofibers, whereas they not only become desialylated, but also are transduced at much higher rates in the setting of hindlimb ischemia. 16 This is consistent with reports indicating that ischemia induces desialylation of cell-surface glycans, 21 thus unmasking the primary receptor for AAV9 and increasing transduction efficiency.
Ischemia is also known to increase vascular permeability, 22 and our previous work had identified increased vascular permeability secondary to ischemia as another potential mechanism that might contribute to the remarkable increase in AAV9-mediated gene expression observed in ischemic versus non-ischemic hindlimbs. 16 Histamine is well known to increase vascular permeability and has previously been used to enhance AAV-mediated gene transfer in vivo. 23 In the present study, we aimed to determine whether increased vascular permeability and/or desialylation might function alone or synergistically to increase AAV9-mediated transduction in a mouse hindlimb ischemia model of PAD. cells, and was then purified by ammonium sulfate fractionation and iodixanol gradient centrifugation. 25 The titer of the AAV vector (viral genomes/mL) was confirmed by a quantitative real-time polymerase chain reaction (qPCR). 26 The primers used for amplifying luciferase were: 5′-AGAACTGCCTGCGTGAGATT-3′ (forward) and 5′-AAAACC GTGATGGAATGGAA-3′ (reverse). Known copy numbers (10 5 to 10 8 ) of a reference plasmid carrying the luciferase cDNA were used to construct standard curves for quantification.
| Animal procedures and vector administration
The animal protocols used in the present study were approved by 
| Evans blue dye assay
The Evans blue assay was performed as described previously. 16 Briefly, animals were anesthetized and maintained on 1- 
| Bioluminescence imaging (BLI)
Luciferase expression was serially assessed in live mice at 7 and 14 days post AAV9/CK6/Luc injection using an in vivo BLI system (IVIS Spectrum; Caliper Life Sciences, Hopkinton, MA, USA) as described previously. 27 2.6 | Quantitative luciferase activity assay 2.7 | Determination of AAV vector genome copy number per μg genomic DNA
The AAV2 genomic backbone AAV/CK6/Luc was cross-packaged into AAV9 capsids for injection as described above. Two weeks after vector administration, total genomic DNA from a panel of tissues was prepared using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA).
Real-time PCR using iTaq Universal SYBR Green Supermix (Bio-Rad) was performed on a CFX Connect system (Bio-Rad). The primers used for amplifying the firefly luciferase gene were: 5′-AAGATTCAAAGTGCGC TGCTGGTG-3′ (forward) and 5′-TTGCCTGATACCTGGCAGATGGAA-3′
(reverse). The results are expressed as mean AAV vector genome copy numbers per host genome.
| Statistical analysis
Data are expressed as the mean ± SEM. Statistical analyses of data were performed using Student's t test or one-way analysis of variance followed by the Student-Newman-Keuls test, as appropriate. p < 0.05 was considered statistically significant.
3 | RESULTS
| Effect of His dose on vascular permeability
To determine the optimal concentration of His for increasing vascular permeability in mouse skeletal muscle, three different doses of His were injected into left hindlimb muscle and Evans blue assays were performed. Example images of isolated GA and TA muscles are shown in the Supporting information ( Figure 1 ).
As shown in Figure 1A , the Evans blue dye concentration in treated muscles showed a dose-dependent increase with higher doses of His (2 μM: 4.58 ± 0.87 μg/ml, 100 μM: 6.64 ± 0.71 μg/ml and 10 mM: 8.70 ± 3.24 μg/ml), whereas Evans blue concentrations in untreated right hindlimb muscles remained essentially unchanged.
However, only the left hindlimb muscles injected with His at 100 μM reached statistical significance compared to Evans blue concentrations in the untreated muscles of the right hindlimb (p < 0.05). When the ratios of Evans blue concentrations were compared in His-treated versus untreated muscles, the ratio was higher in the group of muscles treated with 100 μM His Two hours later, mice were humanely killed and TA and GA muscles were harvested for the Evans blue assay and Mal-1/Ecl staining.
In these experiments, the left hindlimb muscles injected with NS yielded Evans blue contents that were almost identical to uninjected 
| Desialylation versus vascular permeability on AAV9-mediated gene delivery in skeletal muscle
To compare the effects of "unmasking" the endogenous AAV9
receptor by Neu versus increased vascular permeability by His on AAV9-mediated gene expression, the optimized doses of His and
Neu were injected IM 2 h before the IV injection of an AAV9 vector expressing firefly luciferase in studies of a 2 × 2 factorial design.
At 7 and 14 days post AAV9 injection, luciferase expression was monitored by non-invasive in vivo BLI. In Figure 5A and 5B, as muscles. The remaining two groups showed activity levels in the
LGA and LTA muscles that varied little from those found in the untreated contralateral right hindlimbs. Finally, the quantitative analysis of luciferase activity in Figure 9A showed that the Neu and His+Neu groups had much higher luciferase expression in LGA and LTA than RGA and RTA, or from hindlimbs in 
| DISCUSSION
For the treatment of PAD, the systemic delivery of AAV9 offers an attractive option for selectively targeting therapeutic gene expression to ischemic muscle tissue. In previous work, our group showed that AAV9 vectors harboring a muscle-specific promoter selectively target luciferase activity to ischemic muscle in the mouse hindlimb, with gene expression in ischemic LGA muscles enhanced by 34-fold compared to the fully perfused contralateral RGA. 16 This same study also included experiments with Evans blue dye and fluorescence labeled lectins to identify vascular permeability and desialylation of the cell-surface glycans as potential mechanisms underlying the selective targeting of AAV9 to ischemic muscle.
In the present study, we explored the possibility of reconstituting the ischemic induction of AAV9-mediated transduction using natural biologic interventions known to increase vascular permeability (His) and to desialylate cell-surface glycans (Neu). In studies of a 2 × 2 factorial design, we investigated the effects of the IM injection of Neu and His (alone and in combination) on the efficacy of systemically administered AAV9 vectors carrying a muscle-specific reporter gene.
Our initial experiments were focused on optimizing the doses of His ( Figure 1 ) and Neu administration (Figure 2 ). This was considered necessary to develop an experimental time line that was compatible with the co-administration of both His and Neu. Additional experiments were performed with surrogate assays relevant to AAV9 transduction to confirm that His still increased vascular permeability, even when co-injected with Neu ( Figure 3 ) and that
Neu still mediated desialylation, even when co-injected with His were obtained using in vivo BLI, which may be less accurate and precise than tissue-based assays but has the advantage of being non-invasive, thus enabling longitudinal studies ( Figures 5 and 8 ).
We found that comparisons of left to right hindlimbs by average radiance values at 7 days post AAV injection were highly predictive of the results obtained at 14 days, even though luciferase activity in most groups roughly doubled over this same time period. This finding is consistent with our previous study in ischemic mouse hindlimbs, where average radiance levels at 14 days post injection tended to be higher than the results obtained at 7 days. and 8C). However, the ratios of left to right hindlimb luciferase activity were consistently found to be higher as obtained by the in vitro luciferase assay (60-100-fold differences) than by in vivo BLI (15-30-fold differences). This is not unexpected given that the dynamic range of in vitro luciferase assays can be extended by sample dilution, whereas no analogous optimization step is possible in vivo using BLI. Tissue attenuation of light penetration can also be expected to limit the dynamic range of BLI compared to a relatively transparent in vitro sample assayed in a luminometer. 29 The qPCR results showed that AAV/host genome ratios in left (treated) versus right (untreated)
hindlimbs largely paralleled the results from the luciferase assays.
There was little difference between the negative control and His groups, and every group treated with Neu or His+Neu showed a significantly elevated ratio of AAV to host genomes in treated versus untreated (contralateral) hindlimbs. A consistent finding, however, was that the increase in AAV/host genome ratios in the Neu and His +Neu groups (3.6-8.7-fold in Figure 7B ) was inadequate to fully account for the dramatic increase in luciferase activity in the Neu and His+Neu groups (60-100-fold in Figure 6A ). Assuming a linear response between AAV9 gene dose and reporter gene expression, 30 this result suggests that Neu may enhance AAV9-mediated gene expression by mechanisms other than the increase in transduction rate as a result of desialylation and exposure/activation of the primary AAV9 receptor/attachment factor. Given the results of the experiments in the present study that included His, this additional mechanism would not appear to involve vascular permeability.
Another noteworthy finding from these experiments was that the ratio of reporter gene expression to AAV genomes was approximately 5000-fold higher in the Neu-treated LGA muscles than in livers from the same animals, highlighting the high degree of tissue specificity conferred by the modified muscle creatine kinase promoter.
The mechanisms underlying AAV cellular binding, uptake and subcellular trafficking are extremely complex and have yet to be fully clarified, although the recent discovery of the AAV receptor (AAVR) FIGURE 7 Biodistribution of AAV9-mediated gene expression versus transduction in various tissues. A, intramuscular injection of Neu or His+Neu 2 h before the systemic administration of AAV9 significantly increased luciferase activity in targeted LGA muscles over those injected with NS (vehicle) or His alone. Off-target gene expression was detected at much lower levels (100-400-fold lower) in the heart and liver, whereas luciferase activity was negligible in the spleen, lung, kidney, thymus and brain. B, AAV/host genome ratios in LGA muscles from the four treatment groups are compared with a panel of seven other organs 14 days after IV injection of AAV9 carrying a muscle specific promoter. IM injection of Neu or His+Neu 2 h before the systemic administration of AAV9 significantly increased AAV/host genome ratios in targeted LGA muscles over those injected with NS (vehicle) or His alone. Offtarget AAV9 genomes were detected at similar levels in the spleen, and at much higher levels (10-30-fold higher) in the liver, whereas genome ratios remained consistently low in all other tissues examined (heart, lung, kidney, thymus and brain (*p < 0.05 versus NS, #p < 0.05 versus His, n = 4-6 per group)
in an unbiased genetic screen has yielded new insight. 31 The AAVR was shown to play an essential role in infection by multiple AAV serotypes (including AAV1, AAV2, AAV3b, AAV5, AAV6, AAV8 and AAV9) with respect to mediating rapid endocytosis from the plasma membrane and trafficking to the trans-Golgi network. Subsequent work showed that AAVR is an N-linked glycosylated membrane protein using the host cell endosomal pathway to cycle between the plasma membrane and the trans-Golgi network. 32 The promoter is highly selective in targeting Neu-treated muscle tissue, with levels of gene expression that are 60-100-fold higher than in untreated muscle or in the next most vulnerable off-target tissues (heart and liver).
Although several hurdles remain, these findings could potentially be used in the future to make muscle-directed human gene therapy more robust and practical by lowering the required dose of AAV9 by some 60-100-fold, at the same time as reducing the potential for undesirable transgene expression in off-target tissues.
